U
Umoja Biopharma
Developing a new approach to cancer therapy that retools a patient’s immune system in vivo, enhancing the body’s natural capacity to fight cancer
About Umoja Biopharma
Umoja Biopharma is a pioneering startup in the field of immunotherapy, specifically focusing on reprogramming T cells within the body to target and eliminate cancer cells. The company's innovative approach involves modifying the patient's immune system in vivo, or within the body, to create lasting remissions. This is a significant departure from traditional immunotherapies, which often involve modifying cells outside the body and then reintroducing them.
Read full description
Umoja Biopharma's primary market is patients with solid tumors and hematological cancers that have not responded well to existing treatments. The company's business model revolves around the development and commercialization of its proprietary CAR T-cell gene therapy platform. This platform is designed to be scalable and capable of treating cancers at every stage, making it a potentially versatile tool in the fight against cancer.
The company generates revenue through the development, production, and sale of its therapeutic regimens. As these treatments are developed in-house and are off-the-shelf, they can be produced and distributed more efficiently than therapies that require individual customization for each patient.
In summary, Umoja Biopharma is a cutting-edge startup that is leveraging the power of the immune system to revolutionize cancer treatment. Its innovative approach and proprietary technology position it well in the rapidly growing field of immunotherapy.
At a glance
- Founded
- 2019
- Headquarters
- Seattle, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Latest news
Press, funding announcements and product moves mentioning Umoja Biopharma.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A12 investors entered at this stage
MPM BioImpact
Qiming Venture Partners USA
SoftBank Vision Fund
Temasek
SoftBank
Alexandria Venture Investments
Emerson Collective
Cormorant Asset Management
Casdin Capital
RTW Investments
Presight Capital
CaaS Capital Management
Series B and later6 investors entered at this stage
DCVC Bio
Double Point Ventures
University of Minnesota Twin Cities
ARK Invest
Myeloma Investment Fund
K2 HealthVentures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
13 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Umoja Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Umoja Biopharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.